CD8A and neoplasm: Similarly, a study by Liu et al. found that anti-CD47 antibody treatment inhibits tumor progression by enhancing the antigen-specific CD8+ T-cell response through dendritic cell-mediated presentation of tumor antigens to T-cells (72).